Literature DB >> 8671319

Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses.

C Rice1, S Killick, D Hickling, H Coelingh Bennink.   

Abstract

A randomized, double-blind, group-comparative study was performed over a 6 month period to compare ovarian suppression and vaginal bleeding during the use of three oral contraceptives containing doses of 30, 50 or 75 micrograms desogestrel. A total of 44 female volunteers with regular cycles and established ovulation by ultrasonography were recruited from an out-patient clinic in a university hospital and asked to participate in the study. Ultrasonography and serum oestradiol and progesterone measurements were performed during two assessment periods. The 75 microgram dose showed complete suppression of ovulation and a more acceptable bleeding pattern than the lower doses. The 75 microgram dose of desogestrel is the most promising dose for the development of a new progestogen-only oral contraceptive agent.

Entities:  

Keywords:  Bleeding; Clinical Research; Comparative Studies; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Contraceptive Mode Of Action; Desogestrel; Developed Countries; Diseases; Double-blind Studies; Europe; Examinations And Diagnoses; Family Planning; Laboratory Examinations And Diagnoses; Laboratory Procedures; Menstruation; Northern Europe; Oral Contraceptives; Ovulation Suppression; Reproduction; Research Methodology; Research Report; Signs And Symptoms; Studies; United Kingdom

Mesh:

Substances:

Year:  1996        PMID: 8671319     DOI: 10.1093/oxfordjournals.humrep.a019245

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette and Liseta.

Authors:  C J Timmer; N Srivastava; T O Dieben; A F Cohen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Oct-Dec       Impact factor: 2.569

2.  Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers.

Authors:  María Ángeles Pena; Emilio Sanz; Silvia Francisco; Ainhara Alonso; Zurine Abajo; Izaskun Felipe; Jaume Pascual; Digna Tost; Sandra Bailac
Journal:  Sci Pharm       Date:  2012-03-01

Review 3.  Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?

Authors:  Rossella E Nappi; Gabriele S Merki-Feld; Erica Terreno; Alice Pellegrinelli; Michele Viana
Journal:  J Headache Pain       Date:  2013-08-01       Impact factor: 7.277

4.  Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.

Authors:  S Palacios; E Colli; P A Regidor
Journal:  PLoS One       Date:  2020-06-29       Impact factor: 3.240

5.  A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg.

Authors:  Santiago Palacios; Enrico Colli; Pedro-Antonio Regidor
Journal:  Arch Gynecol Obstet       Date:  2019-11-14       Impact factor: 2.344

Review 6.  Contraception During Perimenopause: Practical Guidance.

Authors:  Giovanni Grandi; Pierluigi Di Vinci; Alice Sgandurra; Lia Feliciello; Francesca Monari; Fabio Facchinetti
Journal:  Int J Womens Health       Date:  2022-07-15

Review 7.  The clinical relevance of progestogens in hormonal contraception: Present status and future developments.

Authors:  Pedro-Antonio Regidor
Journal:  Oncotarget       Date:  2018-10-02

Review 8.  Bone health in estrogen-free contraception.

Authors:  P Hadji; E Colli; P-A Regidor
Journal:  Osteoporos Int       Date:  2019-08-24       Impact factor: 4.507

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.